[Novo Nordisk](https://www.novonordisk.com)

September 2021 | August 2025 | August 2026

DKK 6–22 million per grant (approx. €800,000–€3 million) over 3–5 years; total program budget DKK 89 million

Supports large, non-commercial clinical trials in Denmark to improve patient care through innovative medicines and technologies.

Forecasted: All dates are projected; check the program page for confirmation.

--- ## Description This grant supports investigator-initiated, large-scale clinical trials in Denmark that are not commercially driven, aiming to advance patient treatment through new medicines, medical technologies, or innovative therapeutic approaches. The program welcomes both single-center and multicenter national trials, and for international multicenter trials, the main applicant and the trial must be anchored at a Danish hospital. For international studies led outside Denmark, only the Danish project component is eligible for funding, and the main applicant must be a key Danish-based investigator. The grant emphasizes rigorous clinical and translational research, scientific independence, and open data sharing upon trial completion. --- ## Due Dates - September 2021: Full application deadline (historical; call closed 14:00 CEST) - August 2025: Full application deadline (call closed 14:00 Copenhagen time) - August 2026: Full application deadline (anticipated/projected) *All dates are projected based on the annual cycle; check the program page for updates.* --- ## Funding Amount - Individual grants: DKK 6–22 million (approx. €800,000–€3 million) per project - Project duration: 3–5 years - Total annual program budget: DKK 89 million Eligible expenses include staff (excluding the main applicant’s own salary), research and technical assistance, equipment (up to 20% of total budget), operating costs, travel, publication costs, and limited administrative support (not for Danish universities). --- ## Eligibility - **Main applicant:** Must be an MD specialist physician with documented research leadership experience, employed at a Danish hospital where the trial is anchored. - **Project:** Must be a non-commercial clinical trial conforming to Good Clinical Practice (GCP) guidelines, with a detailed protocol, power calculation, data management, and statistical analysis plan. - **International trials:** Main applicant and trial must be based in Denmark; for international trials led outside Denmark, only the Danish component is funded if the main applicant is a key Danish-based investigator. - **Co-applicants:** Up to four allowed; project employees (including postdocs and PhD students) cannot be co-applicants. - **Other:** Applicants with an active grant may only apply for a new grant during the final year of the current award, with no overlap in grant periods. **Not eligible:** Trials with an industrial/commercial purpose, or those primarily for product development or implementation. --- ## Application Process - Applications must be submitted via the [NORMA application system](https://norma.novonordiskfonden.dk). - All materials must be in English. - Mandatory uploads: Project protocol, CVs, sponsor letter from institutional head, and other required documentation. - All clinical trials funded must be registered on [ClinicalTrials.gov](https://clinicaltrials.gov/) or the [EU Clinical Trials Information System (CTIS)](https://euclinicaltrials.eu/) before activation. - Data sharing: Anonymized data from funded trials must be made publicly available after trial completion (e.g., via [Zenodo](https://zenodo.org/)). - Applicants are responsible for ensuring all regulatory approvals are in place before grant activation. - Only one application per applicant per call is allowed. --- ## Additional Information - The grant is administered by the [Committee on Clinical and Translational Medicine](https://novonordiskfonden.dk/en/committees/committee-on-clinical-and-translational-medicine/). - Applications are evaluated on scientific originality, relevance, impact, approach, environment, and applicant track record. - Main applicants cannot apply for their own salary; this must be covered by their institution. --- ## External Links - [Grant Program Page](https://novonordiskfonden.dk/en/grant/investigator-initiated-clinical-trials/) - [Application Guidelines (PDF)](https://novonordiskfonden.dk//app/uploads/Guidelines-for-applicants-Investigator-Initiated-Clinical-Trials-2025-2.pdf) - [Rules, Grant Administration and FAQ](https://novonordiskfonden.dk/en/how-we-work/what-are-grants/) - [NORMA Application Portal](https://norma.novonordiskfonden.dk) - [Zenodo Open Data Repository](https://zenodo.org/) - [ClinicalTrials.gov](https://clinicaltrials.gov/) - [EU Clinical Trials Information System (CTIS)](https://euclinicaltrials.eu/) --- ## Contact Information | Name | Role | Email | Phone | |--------------------------------------|------------------------------------------------|------------------------------|---------------------| | Ursula Bach | Senior Grant Manager, Grant Management | [urba@novo.dk](mailto:urba@novo.dk) | +45 35 27 66 00 | | Jens Peter Holst Lauritsen | Scientific Manager, Clinical Medicine & Diabetes| [jlrt@novo.dk](mailto:jlrt@novo.dk) | +45 35 27 66 00 | | Novo Nordisk Foundation (main office)| General inquiries | [info@novonordiskfonden.dk](mailto:info@novonordiskfonden.dk) | +45 35 27 66 00 | For further details, consult the [Novo Nordisk Foundation grants page](https://novonordiskfonden.dk/en/grant/investigator-initiated-clinical-trials/).

Investigator Initiated Clinical Trials

Sign in to see full grant listing